Neosoma adds Debbie Millin and Frederick Driscoll to its Board of Directors

– USA, MA –  Neosoma, Inc., an innovative medical technology company focused on helping clinicians advance the treatment of brain cancers, today announced the appointment of Debbie Millin and Frederick Driscoll to its board of directors.

“Key to executing on our strategy is ensuring that the company has a diverse and experienced board of directors. Debbie and Fred each bring a wealth of operational and strategic expertise to scaling software and life sciences businesses, as well as a passion for our mission. Together, their involvement sets Neosoma up well for our next phase of growth; I couldn’t be more excited,” said CEO and co-founder, Ken Kolodziej.

About Debbie Millin

Debbie Millin has made a career of scaling rapid-growth companies in disruptive industries, leading two separate companies to be the #1 fastest-growing private company in Massachusetts. She served as the founding Chief Operating Officer at Globalization Partners (G-P), where she grew the company from 3 people to a valuation of $4.2 billion, and received multiple awards for the company’s extraordinary growth, innovation, and culture. Debbie also serves on multiple committees for the Board of Trustees at the Museum of Science in Boston, and the Harvard Club of Boston. She is an alumna of Bentley University and Harvard Business School.

About Frederick Driscoll

Frederick Driscoll is an accomplished healthcare executive with more than 25 years of financial management of life sciences companies. Mr. Driscoll served as Chief Financial Officer at Flexion Therapeutics in 2021 where he was a member of the merger and acquisitions executive team that executed the $1bn sale of the Company to Pacira BioSciences. He previously served as Flexion’s Chief Financial Officer from 2013 to 2017; during his tenure, he spearheaded an initial public offering in 2014 and was at the financial helm through the commercial launch of ZILRETTA.

Mr. Driscoll earned a B.S. in accounting and finance from Bentley University and currently serves as a member of the board of directors of Cue Biopharma, Cellectar Biosciences, Inc., and MEI Pharma.

About Neosoma

Neosoma is focused on advancing the treatment of brain cancers through an integrated portfolio of innovative, artificial intelligence-based software products combined with a Clinical Management Software Platform. Neosoma’s comprehensive SaaS solution is first-of-its-kind technology in the neuro-oncology space, helping physicians to make better treatment decisions to improve clinical outcomes.

Starting with its initial software-based medical device, Neosoma HGG, the company is developing a full suite of software technologies to become the global leader in the neuro-oncology field.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.